Kymera (KYMR) CEO Nello Mainolfi Exercises Options, Sells 30,000 Shares

What Happened

• Kymera Therapeutics CEO Nello Mainolfi exercised 30,000 option shares at $2.08 each (cost $62,400) on 2026-10-01 and sold 30,000 shares in multiple open-market transactions the same day, generating approximately $3,413,916 in gross proceeds. The sales were executed via several transactions at weighted-average prices ranging roughly from $110.93 to $116.16 per share.
• The Form 4 also reports a corresponding derivative disposition of 30,000 shares at $0.00, which reflects cancellation/disposition of the option instrument upon exercise (no cash proceeds).

Key Details

• Transaction date: 2026-10-01 (filed same day; no late filing indicated).
• Option exercise: 30,000 shares @ $2.08 per share (total exercise cost $62,400).
• Open-market sales: 30,000 shares sold in tranches with weighted-average prices reported as $111.44, $112.42, $113.24, $114.43, $115.40 and $116.12; overall gross proceeds ≈ $3,413,916.
• Price ranges for sale tranches (per footnotes): $110.93–111.90; $111.97–112.92; $112.95–113.88; $113.94–114.91; $114.94–115.92; $116.09–116.16.
• Footnotes: Transactions were made pursuant to a Rule 10b5-1 trading plan dated March 24, 2026. The underlying options were fully vested and exercisable.
• Shares owned after the transactions: not provided in the material you supplied.

Context

• This is effectively an exercise-and-sell (cashless-style) event: options were exercised and the resulting 30,000 shares were sold the same day. Sales executed under a pre-established 10b5-1 plan are typically scheduled trades and do not, by themselves, indicate the insider’s current view of the company. Purchases generally carry more direct informational weight than routine sales.